Other Guidelines | Page 53 | European Cystic Fibrosis Society (ECFS)

Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)

Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function

Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

Cystic Fibrosis Related Diabetes; Glucose challenge test; Oral glucose tolerance test.

In vitro 3D culture lung model from expanded primary cystic fibrosis human airway cells

Building global development strategies for cf therapeutics during a transitional cftr modulator era

Citrullination of extracellular histone H3.1 reduces antibacterial activity and exacerbates its proteolytic degradation

Fibrocyte accumulation in the lungs of cystic fibrosis patients

Defective BACH1/HO-1 regulatory circuits in cystic fibrosis bronchial epithelial cells

Newborn screening alone insufficient to improve pulmonary outcomes for cystic fibrosis

first
previous
…
49
50
51
52
53
54
55
56
57
…
next
last